Accumulation of bioactive metabolites in cultivated medical Cannabis

There has been an increased use of medical Cannabis in the United States of America as more states legalize its use. Complete chemical analyses of this material can vary considerably between producers and is often not fully provided to consumers. As phytochemists in a state with legal medical Cannabis we sought to characterize the accumulation of phytochemicals in material grown by licensed commercial producers. We report the development of a simple extraction and analysis method, amenable to use by commercial laboratories for the detection and quantification of both cannabinoids and terpenoids. Through analysis of developing flowers on plants, we can identify sources of variability of floral metabolites due to flower maturity and position on the plant. The terpenoid composition varied by accession and was used to cluster cannabis strains into specific types. Inclusion of terpenoids with cannabinoids in the analysis of medical cannabis should be encouraged, as both of these classes of compounds could play a role in the beneficial medical effects of different cannabis strains.


Introduction
Cannabinoids are the class of terpenophenolic secondary metabolites commonly produced by members of the Cannabis genus [1]. Within this class are specific compounds with notable bioactive effects; these effects often requiring post-biosynthetic processing, i.e. heat, to generate the more bioactive form [2]. Multiple peoples around the world have used the fibers, oils, resins, dried inflorescences and leaves of species within Cannabis for thousands of years [3]. There is some discussion of the number of species in the genus cultivated for use as marijuana, with the most recent assessment supporting one highly variable species, C. sativa, with variants, eg. var. indica as well as a number of strains within that species [4][5][6]. Strains have been selected for the production of hemp fiber or for the production of cannabinoid-containing resin. These two selection paths have isolated strains into types with and without the biosynthetic capability for the production of the psychoactive cannabinoid precursor Δ 9 -tetrahydrocannabinolic acid (THCA) [7]. Cannabis plants containing this compound are called a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 marijuana, Cannabis plants that do not accumulate THCA to an appreciable level, (< 0.3%) are called hemp.
The Cannabis strains used for the production of cannabinoids are dioecious, with the maximal accumulation of these compounds accumulating on the unfertilized female inflorescence. The synthesis and accumulation of the cannabinoids occurs in trichomes on the surfaces of both leaves and inflorescences [8]. These plants are photoperiodic and commercial greenhouse production often utilizes clonally propagated material from female "mother plants" [9]. Cuttings are rooted and grown under vegetative light conditions (18 h or longer of light) for several weeks before the induction to flower. A switch to short day photoperiod, typically 12 h light, initiates floral development. Plants are then maintained for another 9 to 11 weeks and then the entire plant may be harvested and dried.
The biosynthetic pathway of the most abundant members of the cannabinoid class has been determined (reviewed in [2]). A schema of this pathway is presented in Fig 1. The enzymes and many genes for the pathway have been isolated and characterized in detail (reviewed in [10]). This includes the novel polyketide cyclase for the synthesis of olivetolic acid [11,12], and the prenyl transferase, also called cannabigerolic acid synthase, that produces the central precursor cannabigerolic acid (CBGA) [13]. The specific synthases for the production of THCA [14], cannabidolic acid (CBDA) [15] and cannabichromenic acid (CBCA) [16] have also been characterized. Based on inheritance of chemical phenotypes, the genes for THCA synthase (THCAS) and CBDA synthase (CBDAS) are considered co-dominant alleles [7,17]; while the gene for CBCA synthase is an independent locus. However, based on DNA sequencing and analysis of the transcripts expressed in marijuana and hemp samples, multiple linked loci for the THCAS and CBDAS genes are proposed [18,19]. There are published genomes for Cannabis, and the genetic diversity for the biosynthetic pathway of cannabinoids in both marijuana and hemp strains is under investigation [18,20]. laboratory provided access to research space licensed for analysis of the plant material in this report. All material costs and salaries of staff working on this project were paid through the Agricultural Experiment Station at New Mexico State University. RDR is an owner of Rio Grande Analytics, in addition to his full-time position at NMSU, however, Rio Grande Analytics did not provide salary support or have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: This work was possible because research scientists employed at a public university collaborated with two licensed medical marijuana industry members in NM: Rio Grande Analytics and Ultra Health. These commercial entities did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript; they provided no financial support for supplies or salaries. They did provide analysis space and access to medical marijuana plants during their growth cycles. This does not alter our adherence to PLOS ONE policies on sharing data.
The bioactive forms of the cannabinoids are produced following a light or heat induced decarboxylation reaction to generate cannabigerol (CBG), Δ 9 -tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD) or cannabichromene (CBC). Other cannabinoids detected in plant samples include a further oxidation product of Δ9-THC, cannabinol (CBN) and cannabinoids produced from condensation of geranyl diphosphate with a variant of olivetolic acid, divarinic acid which has a propyl side chain instead of the pentyl side chain and results in Δ 9tetrahydrocannabivarin (Δ9-THCV). Based on the diversity of cannabinoid content, five unique chemotypes have been described [21][22][23][24]: chemotype I includes strains with primarily Δ9-THCV, chemotype II includes strains with similar levels of CBD and Δ9-THCV, chemotype III includes the hemp strains with virtually no Δ9-THCV and primarily CBD; chemotypes IV and V are less frequent and include strains with no Δ9-THCV and primarily CBG and strains with no cannabinoids.
In addition to the cannabinoids, medicinal Cannabis samples are also rich in bioactive terpenoids [25]; there appears to be a positive correlation between the accumulation of each of these classes of compounds [1]. The complexity of the terpenoid and cannabinoid composition in these samples should be routinely quantified to accurately and adequately determine the medicinal potential of a particular sample [26]. Inclusion of the terpenoid composition in a characterization of a medicinal marijuana sample also provides information about the provenance of the sample [1], as unique chemical abundances of specific terpenoids are predicted to be associated with chemotypes and species level taxa [5,27]. As the aroma of the plant is largely the result of the terpenoid composition [25], human selections for this plant may have been based in part on the monoterpenoid and sesquiterpenoid based aroma and on the cannabinoid psychoactivity.
Within the past several decades, significant scientific evidence for the medical utility of both the floral material and specific cannabinoids from these plants has been presented for a number of human health diseases and conditions [9,[28][29][30]. In the United States of America, as of 2018, more than half of the states license the use of medical marijuana http://www.ncsl. org/research/health/state-medical-marijuana-laws.aspx; while the U.S. federal government continues to classify marijuana as a Schedule 1 drug https://www.justice.gov/iso/opa/ resources/3052013829132756857467.pdf. As a result, there is very limited reliable data on the chemical composition of Cannabis strains, the variability within the plant for the production of these compounds and the interaction of the environment of production with the chemical quality of a specific strain. Much of the material currently available for medical use was selected from the numerous strains available from the illicit drug growers; understandably, the provenance and genetic backgrounds of these strains are not easily traceable.
Our past experience characterizing the sources of variability for secondary metabolite accumulation in medicinal plants like lavender [31] yerba mansa [32] or in Capsicum cultivars (chile) [33] lead us to investigate the variability for cannabinoid accumulation in medical marijuana produced by licensed growers in New Mexico.
There were several aims for the experiments reported here. We wanted to develop a rapid, reliable and inexpensive method to quantify the important bioactive compounds in medical marijuana, cannabinoids and terpenoids. We wanted to demonstrate the utility of the method using commercial material, available as medical marijuana in New Mexico. These studies were also designed to determine the consistency of total and relative cannabinoid and terpenoid accumulation within a given accession, and to see if leaf levels of cannabinoids could be used to predict eventual floral levels. To answer these questions, the concentration of five cannabinoids, Δ9-THC, CBD, CBG, Δ9-THCV, and CBC were determined in leaf and floral samples from 28 strains, collected at multiple times throughout the year. The terpenoid contents of selected medicinal strains are also presented. We also report here a reliable and sustainable gas chromatography method for the separation and quantification of these five neutral cannabinoids. This method has superior limit of detection (LoD) and limit of quantitation (LoQ) capabilities for these metabolites over the more common liquid chromatographic separations [34]. We present this method as a way to easily monitor both the cannabinoid and terpenoid compositions of medical marijuana plant material https://www.protocols.io/view/cannabinoidand-terpenoid-extraction-and-analysis-rd4d28w.

Plant material
All of the plant material characterized in this report will be referred to as Cannabis, without a species level description. The precise provenance of the plant material is difficult to trace, strain names are not protected, and growers' descriptions of the plant material as "indica dominant" or "sativa dominant" do not necessarily reflect results obtained with genotyping [4].
For the developmental analyses, plants were grown in a commercial greenhouse in central New Mexico, under a medical marijuana producer license from the New Mexico Department of Health. Cuttings were propagated in Coco Air Max for 6 to 8 weeks with a 20 h light photoperiod. Plants were watered daily and were fertilized with Veg A&B and/or Bud A&B (Heavy 16, Signal Hill, CA) at a rate of between 500 and 1500 mg/L depending on the growth stage of the plants. Natural light was supplemented with artificial lighting using 600 watt CFL (compact fluorescent) and/or 1000-watt HPS (high-pressure sodium) lamps. The greenhouse temperature was set to 22˚C; actual temperatures varied somewhat from a low of 17˚C to a high of 33˚C. Relative humidity varied between 35 and 65%. Plants were then transferred into 38 L pots and moved to a 12 h photoperiod to induce flowering. Again, natural sunlight was supplemented with artificial lighting as needed. Leaf and flower samples were collected at the days indicated post floral induction. In some cases, samples were collected from the top (upper third of plant) or bottom (lowest third of plant). For RNA isolation, leaf or flower samples were collected at "early" (4-5 weeks post floral induction), "mid" (6-7 weeks post floral induction, or late (8-11 weeks post floral induction). All of these samples were dried, but not "cured" prior to chemical extraction for metabolites. Samples for RNA extraction were not dried but frozen in liquid nitrogen and stored frozen until extraction.
A second source of plant material includes cured flowers from medicinal marijuana produced by licensed growers throughout the state of New Mexico. This material reflects the medical marijuana commercially available, and represents a wide range of strains. Those samples were submitted by producers as 'cured' medical cannabis. Curing is the method used to properly age and dry cannabis flower prior to consumption. A cured flower will typically have a moisture content of between 3% and 10%. All of the plant material was processed at Rio Grande Analytics, a licensed medicinal Cannabis testing laboratory. If the analyses utilize 'cured' medical cannabis samples that is indicated in the figure or table legend.

Cannabinoid extraction and analysis
Cured/dried flowers or dried leaves were homogenized in 20 mL of reagent-grade acetone using a Polytron Homogenizer (Kinematica). The homogenates were placed on an orbital shaker for 1 h. Samples were diluted in four parts of acetone containing 1 mg/mL chlorophenol and 2 mg/mL phenacetin (ISS1 and ISS2, respectively). The samples were then centrifuged briefly to remove insoluble matter and analyzed using a Varian model 3900 GC-FID with an Rxi-35 column (15 m x 0.25 mm). Ultrapure nitrogen was employed as the carrier gas (flow rate: 1 mL/min). The injection volume was 2.0 μL, split 10, injector temperature 250˚C, FID temperature 300˚C. The temperature gradient for the analysis started at 45˚C (with a 1 min hold), and increased to 240˚at 10˚/min, then increased to 280˚C at 4˚/min, then finally increased to 290˚C at 20˚/min with a one-minute hold. This method proved adequate to separate six of the more abundant cannabinoids (Δ9-THC, CBD, CBC, CBG, Δ9-THCV and CBN) and 21 terpenoids (Table 1). Cannabinoid standards were obtained from Restek (Bellefonte, PA) and Sigma-Aldrich (St Louis, MO); terpenoid standards were obtained from Restek as well. The regression equation parameters for each analyte standard were determined using at least 10 different concentrations between 0 and 520 ng for the terpenoids and between 0 and 3880 ng for the cannabinoids. These parameters predict the mass of the analyte from the GC-FID peak area (y = mx + b; where y is the peak area, m is the slope, x is the mass in ng, and b is the intercept on the y axis). Peak ID is the code for each of the 21 terpenoids (T1-T21) and six cannabinoids (C1-C6), for which a calibration curve was generated.

RNA isolation and analysis
Flowers and leaves were harvested and immediately frozen in liquid nitrogen; RNA was isolated using methods described earlier [35]; the quality of the RNA was confirmed by formaldehyde agarose gel electrophoresis. The primers and conditions for qRT-PCR analysis were developed based on methods described earlier [36]. The primers specific to Cannabis mRNA for the THCAS, CBDAS and the prenyl transferase are listed in Table 2

Detection of terpenoids and cannabinoids in a single GC-FID run
Gas chromatography is a useful approach for quantifying terpenoids and the abundant cannabinoids; however, achieving base line separation of some of the minor cannabinoids, CBC and CBD, can be difficult. Therefore, GC conditions were developed to improve the separation of these analytes. All of the cannabinoids were readily detected at 2 ng, and the peak area for these compounds increased linearly over the range from 2 ng to 3880 ng. Our working range for terpenoid detection was between 0.8 ng to 520 ng. The retention times for 19 terpenoid and 6 cannabinoid standards are presented in Table 1. This table also provides the linear regression parameters for the conversion of GC-FID peak areas to mass quantities of each of these specific metabolites. An example of the resolution of the terpenoids and cannabinoids in a cured Cannabis flower sample is presented in Fig 2. This method provides near baseline separation of the peaks for CBC (C2) and CBD (C3), even in this sample with a relatively high concentration of CBD. All six of the cannabinoids were detected in this strain, and we were able to identify and quantify a number of terpenoid peaks. This strain has relatively high levels of β-myrcene (T4), and α-pinene (T1).
The method described here for the analysis of cannabinoids and terpenoids differs from most published methods in that the cured plant samples were extracted with acetone. Most other published methods utilize methanol, methanol-acetonitrile, or methanol-chloroform as the extraction solvent [5,26,37]. Acetone was selected for this method because it is an excellent solvent for Δ9-THC. Acetone is additionally a less polar solvent, and therefore extracts  fewer sugars and polysaccharides than does methanol. These sugars/polysaccharides build up in a GC column over time, which eventually compromises the performance of the column. Acetone would also be predicted to be an appropriate solvent for terpene/terpenoid extraction. Finally, acetone extracts of terpenes allowed for the detection and quantification of small monoterpenes such as α-pinene whereas methanol was retained longer by the RTx-35 GC column and interfered with the detection of these small terpenes.
A second difference in this assay for quantification of terpenoids and cannabinoids was the use of a single chromatographic system, GC-FID. Other groups have used a GC-MS and HPLC system to characterize both of these classes of metabolites in medical cannabis samples [26], or two different GC runs [5,27]. The use of nitrogen as the carrier gas was a key element in the method described here. Helium gas, which is the more common carrier gas in GC methods for cannabinoids has become difficult and expensive to obtain. Nitrogen gas is readily and sustainably available; further the switch to nitrogen gas improved the separation of the CBC and CBD compounds on the chromatogram. These differences allow this method to recover and detect the lower abundance cannabinoids. One group has quantified terpenoids and cannabinoids using a single GC-FID run [1]; they also used nitrogen as a carrier gas. This group extracted their plant samples sequentially three times with ethanol for a total of 100 mL for a 1 g plant sample. In contrast we use only one acetone extraction, 1 g in 20 mL, homogenized and then shaken on an orbital shaker 1 h. This much simpler protocol recovers equivalent levels of terpenoids and cannabinoids as demonstrated below. There is a limitation to this method; we cannot detect the free acid forms of the cannabinoids, only the neutral forms of the cannabinoids. The heat in the protocol converts all free acid forms to neutral forms. In order to quantify the free acid forms of cannabinoids, the samples must be derivatized prior to GC separation [37].

Comparison of cannabinoid content in leaf and floral samples from medicinal marijuana plants
The cannabinoids present in leaf and floral samples of 16 different medicinal marijuana plants were determined. The levels of six different cannabinoids in floral samples are listed in Table 3 and the levels in leaf samples are listed in Table 4. In both tables the levels are reported as percent of dry weight of the respective organ, these organs were collected from plants at 50 to 65 d post-light induction. As expected the levels of cannabinoids are variable between strains, and the levels in floral tissues are much higher than in leaf tissues. Δ9-THC levels in floral tissues range from 21% in strain Holy Power, to 3% in Juanita. Δ9-THC levels in leaf tissues were generally at least ten fold lower and range from 2.7% in strain Crystal Cookies to 0.3% in Love Lace.
The other important medical cannabinoid CBD, was barely detectable in leaf or floral tissue of most of the strains except Alien Blues, Thunderstruck, Love Lace and Juanita. In three strains, Thunderstruck, Love Lace and Juanita, the CBD levels were higher than Δ9-THC and ranged between 9% and 4.7% CBD. A third cannabinoid, CBC, was present at similar levels in leaves and floral tissues, and varied between strains. Platinum Buffalo had the highest leaf levels, 0.69%, while Bohdi Tree again had the lowest 0.03%. Thunderstruck had the highest CBC levels in floral tissues, 0.62% while Bohdi Tree had the lowest floral levels at 0.05%. CBG the precursor for Δ9-THC, CBD or CBC was also readily detected in floral samples and at trace levels in leaf samples. CBG levels in floral samples ranged between 2.1% in Twisted Velvet to 0.05% in Sour Willie. The variant cannabinoid Δ9-THCV was also detected in floral samples and at much lower levels in leaf samples. The strain Platinum Buffalo had the highest levels in floral samples at 1.3%.
The higher levels of cannabinoids in floral versus leaf tissue is expected and has been described by many other investigators [2,9,22]. The levels of Δ9-THC and CBD among the marijuana plants cultivated in New Mexico for medical applications are similar to the levels reported for cannabinoids in medical marijuana produced in other states and countries [1,26,38]. Typical levels for "high Δ9-THC" (chemotype I) strains range from 15 to 22%, and levels for "equal CBD to THC" (chemotype II) strains range from 5 to 10% of each cannabinoid [22].

Time course for accumulation of Δ9-THC in flowers of medicinal marijuana
The induction of flowering in the clonally propagated plants is initiated by a shift to a shortday photoperiod. Floral and leaf samples were collected from two strains, Sour Willie and Bohdi Tree at multiple intervals following the floral induction. This plant material was collected from greenhouse grown plants. The accumulation of Δ9-THC in these samples was determined and is shown in  (Fig 3B and  3D). This was observed in both Sour Willie and Bohdi Tree and is anecdotal knowledge among producers of this crop. This same pattern of accumulation was observed in two additional strains, increasing the biological replication of this observation. Within each strain there is only a single data point for a floral position at a unique time, we see exactly the same pattern Concentrations expressed as % leaf dry wt (avg ± std dev): Δ 9 tetrahydrocannabinol (Δ9-THC); cannabidiol (CBD); Δ 9 tetrahydrocannabivarin (Δ9-THCV); cannabigerol (CBG); and cannabichromene (CBC). Strains are listed in rank order, high to low Δ9-THC content. The observation that the cannabinoid content increases during floral development has been described by other investigators for plants cultivated in vitro as well as in greenhouse settings [22,39]. The quantification of the variability within the plant for floral content of cannabinoids has not been described in the literature previously. The Δ9-THC content in flowers from the upper levels of the plant was close to twice as high as that in flowers from lower levels of the plant; this was observed in two distinct strains.
Given the somewhat unusual sourcing of plants grown in medical marijuana facilities, the ability to predict whether a particular plant will produce flowers with high levels of CBD or Δ9-THC is desirable. For example, does the cannabinoid content of vegetative leaves, those on the plant prior to flower induction predict the cannabinoid content of the mature flowers that develop later on that plant. A comparison of the levels of CBD in vegetative leaves and mature flowers is plotted for samples from 16 strains (Fig 4). There is a positive correlation between the CBD content of leaf and flower samples, with an R 2 value of 0.92. If a strain is going to have primarily Δ9-THC in its flowers, there will be virtually no CBD in its vegetative leaves. Conversely, if a strain is going to have appreciable levels of CBD in its flowers, then the vegetative leaves will have at least 0.5% CBD content. We also tested for a correlative relationship

Terpenoid content and composition in medical cannabis
A detailed analysis of the terpenoid and cannabinoid content of commercially generated medical Cannabis floral samples was conducted. The aim of this analysis was to compare/contrast the terpenoid composition of these samples among the various strains. The growth conditions of the plant, the harvest of the samples and their curing process were all under the purview of the producer. The strain names for these samples are provided in the supporting information (S1 Table), but we have somewhat limited confidence in the provenance of the strain name. However, the chemical composition of this material used medicinally in New Mexico has been accurately determined. In the supplemental material we provide the abundances of 19 terpenoids and 6 cannabinoids determined on 72 strains of medical Cannabis. The totals of these values were plotted to look for correlations in levels (Fig 5).
The total terpenoid content ranged between 0.6 and 3.3%, while the total cannabinoid content ranged between 12.6-31.5% in these samples. We found a slight positive correlation between total cannabinoid content and total terpenoid content (Fig 5), with an R 2 = 0.32. There are limited biosynthetic interactions between these two biosynthetic pathways, so a strong correlation based on shared biochemical pathways is not predicted. One group has reported a positive correlation between the terpenoid and cannabinoid content [1] of selected strains developed in the Netherlands for medicinal uses. Those authors do not consider the abundance of these metabolites to be linked metabolically either. The positive association between the abundance of terpenoids and cannabinoids in Fig 5 probably reflects increased production of all metabolites, including oils in larger healthier floral buds.
We also tested for chemotypes within the medical cannabis population based on terpenoid profiles. For that analysis we clustered the Cannabis strains using the relative abundance of 19 unique terpenoids in 72 different strains. The dendrogram that resulted from this analysis is presented in Fig 6. The specific composition and strain identifications are presented in supporting information (S1 Table). Pie charts for selected strains are presented along with the color code for the terpenoid composition in S1 Table. As demonstrated in Fig 6, there were three major clades or chemotypes: a type rich in β-myrcene and α-and β-pinenes (30 strains); a type rich in terpinolene (10 strains); and a type rich in d-limonene and β-caryophyllene (32 strains). We also noted two sub-types with reduced statistical support, an α-and β-pinene rich clade (9 strains); and a β-myrcene rich clade (21 strains). We did not test plants with high CBD/low Δ9-THC content and it is likely that additional terpenoid chemotypes will be found in those plants. The biosynthetic pathway for the monoterpenoids and sesquiterpenoids present in the Cannabis samples are highly interrelated and positive and negative correlations between the accumulations of specific compounds are expected.
Several other groups around the world have used terpenoid profiles to categorize Cannabis strains [1,22,26,40]. In these cases the authors used a principal components analysis approach to identify metabolites important in either clustering or discriminating specific strains. Clustering analysis of medicinal Cannabis samples from Canada identified β-pinene, β-myrcene, d-limonene, and β-caryophyllene among other terpenoids as important discriminators [26]. PCA and hierarchical clustering of 11 medicinal Cannabis samples from the Netherlands also demonstrated the importance of terpenoids in the classification of Cannabis strains; again α- and β-pinene, β-myrcene, d-limonene, and β-caryophyllene were noted among other metabolites [1]. Recently, a PCA and hierarchical analysis of 30 cultivars from a medical Cannabis dispensary in California also identified five major groups based on the abundance of 16 terpenoids in these samples [40]. Our approach of agglomerative clustering and then inspection of pie chart displays of terpenoid composition, allowed us to identify the clades in the trees with their most abundant terpenoid.

Transcriptional control of cannabinoid biosynthetic genes
The transcript abundance of three cannabinoid biosynthetic genes, THCAS, CBDAS, and prenyl transferase was determined using qRT-PCR. The levels of these transcripts were determined in four strains, two producing high Δ9-THC levels in flowers (Platinum Scout and Holy Power) and two producing high CBD levels in their flowers (Love Lace and Thunderstruck). Plant samples for these studies were collected from greenhouse grown plants. Transcript levels for these three genes were quantified in leaves (Fig 7) and three different development stages in floral tissues (Fig 8A-8C).
Transcripts for all three genes were detected in leaves of all four strains. The level of CBDAS was the lowest of the transcripts in all four strains. The levels of transcripts for prenyl transferase and THCA synthase were similar within a strain. The two strains that accumulate CBD, Love Lace and Thunderstruck, had similar patterns of expression of all three genes, and the level of CBD synthase was higher in these two strains than in the strains that are higher in Δ9-THC. Platinum Scout, a high Δ9-THC strain, had the highest transcript levels for THCAS and prenyl transferase among the four strains. The Δ9-THC levels in the leaves of Platinum Scout are the highest of the four strains tested in this assay (Table 4).
Transcripts for all three genes were detected in the flowers of all four strains with notable variations. Maximal accumulation of a transcript occurred early in floral development and transcript levels decreased over time. This pattern was observed in all four strains for THCAS and for prenyl transferase (Fig 8A and 8C). Levels of CBDAS were also observed to follow this same developmental pattern in the two high CBD strains, Love Lace and Thunderstruck, while the levels of transcripts for CBDAS in Platinum Scout and Holy Power were barely detected ( Fig 8B). The absolute levels of transcripts in leaves for these enzymes were 10 to 100-fold lower than in the floral RNA samples. This reflects the much greater abundance of the cannabinoids in the floral samples versus the leaf samples (Tables 3 and 4).
These results suggest that transcriptional regulation of the cannabinoid biosynthetic genes plays a role in the accumulation of Δ9-THC and CBD in the inflorescences of these plants. Transcript levels were higher in floral tissues than leaf tissues, and transcript accumulation of THCAS was much higher in lines that accumulate higher levels of Δ9-THC, and a similar relationship for CBDAS. Also, transcripts accumulated early in floral development with decreased transcript abundance as the flower matures, suggests that the enzymes translated from these transcripts persist in the flowers and continue to support cannabinoid biosynthesis. The genes and enzymes for capsaicinoid biosynthesis in fruit of Capsicum sp. follow a similar pattern, transcription peaks of genes for biosynthetic enzymes precede the metabolite accumulation [35, 41, 42,].
A few other groups have investigated the transcription of cannabinoid biosynthetic genes using qRT-PCR approaches, however in all of those cases, the levels of transcript are reported in relative terms not absolute amounts as we do here. This method difference may be the basis for some of the different results reported by these groups. THCAS and CBDAS levels in trichomes in flowers were described as stable during the latter stages of floral development in the C. sativa strain Bediol [43]. These authors also reported higher levels of THCAS and CBDAS in leaves versus flowers or flower trichomes, which is quite the inverse of the results reported here for four separate strains of Cannabis (Figs 7 and 8). The increase in CBDAS transcripts in flowers of hemp strains relative to THCAS transcripts in flowers of marijuana strains has been reported in a transcriptomic study [18] and in a gene mapping study [19]. A comparison of THCAS and CBDAS transcript levels among a number of strains that differ in the accumulation of Δ9-THC and CBD, revealed no association between final metabolite levels and transcript abundances in floral RNA [17]. Again we report here a positive relationship between transcript levels for THCAS or CBDAS and relevant metabolite accumulation. The difference in this case may again be due to the quantification of transcripts, as we determine absolute mass amounts and other groups report relative expression that has been normalized by a range of factors.
In summary we report a simple, robust and reliable method for the chemical characterization of two classes of bioactive compounds in medical Cannabis samples, terpenoids and cannabinoids. Given the myriad of health conditions treated by medical marijuana, detailed and complete compositional analyses are essential to determine the efficacy of this material for those conditions, and the optimal strain for specific conditions. The opportunity to predict high CBD floral samples from analyses on vegetative leaves should be explored further as a way to help producers increase the availability of this medically important cannabinoid. Flowers (upper portion of the plant) and leaves (prior to floral induction) were collected from 21 Cannabis strains. The average floral content of each strain (n = 3-9) and the average leaf content (n = 3-9) are plotted. (TIF) S1 Table. Cannabinoid and terpenoid composition in flower samples as cured commercially available medicinal marijuana. The terpenoid and cannabinoid abundances are reported as % dry wt for 72 strains, listed alphabetically by strain name, rows 2-73. The relative abundances of the terpenoids (% of total terpenoid) of these same samples are presented in rows 78-168. The results are organized by terpenoid type detected following the hierarchical clustering. Representative pie charts for the terpenoid composition are provided for each of the four terpenoid types: pinene, myrcene, terpinolene, and caryophyllene-limonene. A key to the color code for the pie chart is provided.